상세정보
- |Home >
- 상세정보
부가기능
In Defense Of ``Me-Too'' Drugs: Is Primary Care Losing Out To Rare Disease R&D? Regulatory and financial incentives have sparked major investment in orphan drug development. One-third of the new molecular entities and novel biologics approved by FDA in the past five years have been orphan drugs. But now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?
기사 상세정보
소장정보
- 소장정보
| No. | 권호·제본정보 보기 | 소장처 | 소장사항 | 청구기호 | 구독 | 최근입수호 |
|---|---|---|---|---|---|---|
| 1 | 중앙도서관/3층 외국학술지지원센터/ | 610 I35 | 구독중단 | v.34 no.11 |
하단메뉴
